Associate Professor of Medicine, Massachusetts General Hospital
Oncology
Dr. Andrew X. Zhu, MD
|
|
Give Review
Andrew is an expert in the field of Oncology. He graduated from Beijing Medical University. Andrew X. Zhu is a published doctor and has 102 publications published. The lastest was: 'Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.' He is registered with Medicare.
Publications
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatoCellular carcinoma.
- Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced HepatoCellular Carcinoma: A Pilot Compara...
- Safety and Efficacy of 70-150 μm and 100-300 μm Drug-Eluting Bead Transarterial Chemoembolization for HepatoCellular Carcinoma.
- Measuring treatment response to systemic therapy and predicting outcome in biliary tract Cancer: comparing tumor size, volume, density, and metabolism.
- YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.
- Erratum to: The Ability to Diagnose Intrahepatic CholangioCarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced HepatoCellular Carcinoma.
- Microsatellite instability in gallBladder carcinoma.
- Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic Cancer.
- CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice.
- The Ability to Diagnose Intrahepatic CholangioCarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.
- Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells?
- Prospective Trial with Optical Molecular Imaging for Percutaneous Interventions in Focal Hepatic Lesions.
- High lung shunt fraction in coloRectal liver tumors is associated with distant metastasis and decreased survival.
- Hepatocellular Carcinoma: Can Circulating Tumor Cells and Radiogenomics DeLiver Personalized Care?
- A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatoCellular carcinoma.
- Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary Cancer.
- Radiation Therapy for Liver Tumors: Ready for inclusion in Guidelines?
- Genomic Profiling of Intrahepatic CholangioCarcinoma: Refining Prognosis and Identifying Therapeutic Targets.
- Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder Cancer.
- Immune checkpoint blockade in hepatoCellular carcinoma: Current progress and future directions.
- Fractal Analysis of CT Perfusion Images for Evaluation of Antiangiogenic Treatment and Survival in Hepatocellular Carcinoma.
- A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreat...
- Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatoCellular carcinoma.
- An Emerging Role for Radiation Therapy in the Treatment of HepatoCellular Carcinoma and Intrahepatic Cholangiocarcinoma.
- A Nomogram to Predict Long-term Survival After Resection for Intrahepatic CholangioCarcinoma: An Eastern and Western Experience.
- Mutational analysis and clinical correlation of metastatic colorectal Cancer.
- Fractal Analysis of Contrast-Enhanced CT Images to Predict Survival of Patients with Hepatocellular Carcinoma Treated with Sunitinib.
- Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangioCarcinoma.
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2 in Patients with Advanced Hepatocellular Cancer.
- Phase 1 study of N (1),N (11)-diethylnorspermine (DENSPM) in patients with advanced hepatoCellular carcinoma.
- Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer.
- Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis.
- A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic Neuroendocrine tumor.
- Recurrence after operative management of intrahepatic cholangioCarcinoma.
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
- Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
- Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced HepatoCellular Carcinoma: A Phase II Study.
- Targeting the HGF/c-MET Pathway in HepatoCellular Carcinoma.
- Factors Affecting Survival following Chemoembolization with Doxorubicin-eluting Microspheres for Inoperable HepatoCellular Carcinoma.
- Combining transarterial chemoembolization with radiofrequency ablation for hepatoCellular carcinoma: one step forward?
- First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced HepatoCellular Carcinoma.
- New agents on the horizon in hepatoCellular carcinoma.
- Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine Tumors.
- Established and Novel Imaging Biomarkers for Assessing Response to Therapy in HepatoCellular Carcinoma.
- Sorafenib use in hepatoCellular carcinoma in Japan: early experience and impact on clinical practice.
- Molecularly targeted therapy for advanced hepatoCellular carcinoma in 2012: current status and future perspectives.
- Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer.
- IDH mutations: new genetic signatures in cholangioCarcinoma and therapeutic implications.
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in CholangioCarcinoma Identified Through Broad-Based Tumor Genotyping.
- Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic Cancer.
- Targeting insulin-like growth factor axis in hepatoCellular carcinoma.
- Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment.
- Phase 1/2 study of everolimus in advanced hepatoCellular carcinoma.
- Monitoring Response to Antiangiogenic Treatment and Predicting Outcomes in Advanced HepatoCellular Carcinoma Using Image Biomarkers, CT Perfusion, Tumor Density, and T...
- Exploratory Analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
- Development of molecularly targeted therapies in biliary tract Cancers: reassessing the challenges and opportunities.
- Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatoCellular carcinoma.
- A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatoCellular carcinoma.
- A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid Tumors.
- Phase II study of darinaparsin in patients with advanced hepatoCellular carcinoma.
- Intrahepatic cholangioCarcinoma.
- Genetics of biliary tract Cancers and emerging targeted therapies.
- A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
- Systemic treatment of hepatocellular carcinoma: dawn of a new era?
- New trends and novel treatment for hepatoCellular carcinoma: a global perspective.
- Current management of gallBladder carcinoma.
- Metabolic syndrome and hepatoCellular carcinoma: two growing epidemics with a potential link.
- Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic coloRectal adenocarcinoma to the liver.
- Accomplishments in 2008 in the management of hepatobiliary Cancers.
- Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving Systemic therapy for advanced hepatocellular carcinoma.
- Development of sunitinib in hepatoCellular carcinoma: rationale, early clinical experience, and correlative studies.
- Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatoCellular carcinoma: a phase II study.
- NCCN clinical practice guidelines in oncology: hepatobiliary Cancers.
- Commentary: Sorafenib use in patients with advanced hepatoCellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
- Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular Cancer.
- A proposed staging System for intrahepatic cholangiocarcinoma.
- Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid Tumors.
- CholangioCarcinoma: current and novel imaging techniques.
- MDM2 promoter polymorphism and pancreatic Cancer risk and prognosis.
- Expanding the treatment options for hepatoCellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation.
- Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma Cells.
- Systemic therapy for biliary tract Cancers.
- Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatoCellular carcinoma.
- Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder Cancer.
- Development of sorafenib and other molecularly targeted agents in hepatoCellular carcinoma.
- Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic Cancer.
- Phase 2 study of cetuximab in patients with advanced hepatoCellular carcinoma.
- Advanced hepatocellular carcinoma: CT perfusion of Liver and tumor tissue--initial experience.
- Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid Tumors.
- Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal Cancer.
- Phase II study of recombinant human endostatin in patients with advanced neuroendocrine Tumors.
- Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
- A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine Tumors.
- Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal Cancer.
- Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the Liver.
- Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatoCellular carcinoma.
- Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal Cancer.
- Forty-Year Trends in CholangioCarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.
- Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma.
- CT-Guided Percutaneous Microwave Ablation of Tumors in the Hepatic Dome: Assessment of Efficacy and Safety.
Schools
Beijing Med University China
Mem Sloan Kettering Cancer Center
University Of Mn Med School
Yale New Haven Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Memorial Sloan-Kettering Cancer Center -
Yale-New Haven Hospital -
University of Minnesota -
Beijing Medical University
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1699741769 | |
| NPPES Provider LastName | ZHU | |
| NPPES Provider FirstName | ANDREW | |
| NPPES Provider ZIPCode | 021142696 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 425.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699741769 |
| Last Name Of The Provider | ZHU |
| First Name Of The Provider | ANDREW |
| View All |
Similar Doctors
|
|
Dr. David Frank, OD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dimitrios Spentzos, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Philip W. Kantoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy S. Garrett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. M S. Donnelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Myles A. Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anuj Mahindra, MD
This Doctor is OpenDoctor Recommended.
|